Provided by Tiger Trade Technology Pte. Ltd.

Haemonetics

106.20
-0.1100-0.10%
Post-market: 106.200.00000.00%16:10 EDT
Volume:433.23K
Turnover:45.81M
Market Cap:4.83B
PE:51.80
High:106.87
Open:105.14
Low:103.24
Close:106.31
52wk High:109.57
52wk Low:47.32
Shares:45.45M
Float Shares:44.60M
Volume Ratio:0.69
T/O Rate:0.97%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.05
EPS(LYR):2.05
ROE:11.20%
ROA:6.60%
PB:5.77
PE(LYR):51.80

Loading ...

Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026

GlobeNewswire
·
Jun 15

U.S. RESEARCH ROUNDUP-Ferrari, Hawkeye 360, Micron Technology

Reuters
·
Jun 15

How Investors Are Reacting To BioCryst (BCRX) Expanding Its HAE Prophylaxis Data Across Patient Groups

Simply Wall St.
·
Jun 15

BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

GlobeNewswire
·
Jun 12

Is Haemonetics’ (HAE) Apheresis Reorg Quietly Redefining Its Competitive Edge in Medical Devices?

Simply Wall St.
·
Jun 11

Pharvaris Announces Annual General Meeting of Shareholders

GlobeNewswire
·
Jun 11

Haemonetics announces annual shareholder meeting

Reuters
·
Jun 10

A Look At Intellia Therapeutics (NTLA) Valuation After Phase 3 HAE Success And Equity Raise

Simply Wall St.
·
Jun 10

Haemonetics: Buy Rating Reiterated as New Apheresis Reporting Boosts Transparency; $80 Price Target Maintained

TIPRANKS
·
Jun 08

Sector Update: Healthcare Stocks Higher Late Afternoon

MT Newswires Live
·
Jun 06

Haemonetics Narrows Reporting Structure

MT Newswires Live
·
Jun 05

Haemonetics combines Plasma and Blood Center units into new Apheresis reporting segment

Reuters
·
Jun 05

Haemonetics Updates Financial Reporting Segments

THOMSON REUTERS
·
Jun 05

Haemonetics - to Report Under New Segment Structure Beginning Q1 FY2027

THOMSON REUTERS
·
Jun 05

Haemonetics CEO Simon to speak at Goldman Sachs Global Healthcare Conference

Reuters
·
Jun 03

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

GlobeNewswire
·
Jun 01

Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026

GlobeNewswire
·
May 29

Haemonetics Is Maintained at Neutral by Citigroup

Dow Jones
·
May 29

New Data Highlights Heavy Burden of Injectable Treatments for Young HAE Patients

Deep News
·
May 28

Haemonetics price target raised to $70 from $64 at Citi

TIPRANKS
·
May 28